Minimally Invasive Surgery for Lung Cancer: A Comprehensive Overview

In the fight against lung cancer, advances in medicine have brought a glimmer of hope. Although epidemiological data show that the incidence and mortality of lung cancer remain high, improvements in treatment have significantly increased survival rates. Especially for early-stage patients (Stage I and II), surgical resection is the preferred treatment. Whether using traditional thoracotomy or the widely adopted thoracoscopic technology, radical resection can be achieved. Thoracoscopic surgery, characterized by minimal invasiveness, enables faster recovery.

For very early-stage lung cancer, such as carcinoma in situ or minimally invasive adenocarcinoma, the 5-year survival rate after resection can even reach 100%. Even for early invasive cancer, surgical resection can increase the 5-year survival rate to 85-90%. In contrast, chemotherapy alone has a general effectiveness rate of only 30%-40%.

Understanding Minimally Invasive Surgery

Minimally invasive surgery has achieved major breakthroughs. Assisted by thoracoscopy, it requires only a small 3 cm incision. It reduces the need for transfusion — 95% of patients do not require it. Operation time is shortened to within 2 hours, and hospital stay is reduced from two weeks to one week. It improves radicality, increasing the 5-year survival rate by 6% and significantly enhancing quality of life.

Benefits of Minimally Invasive Surgery

Ultra-minimally invasive surgery has revolutionized lung cancer treatment. It adopts general anesthesia without endotracheal intubation, eliminating the need for thoracic drainage tubes and urinary catheters. Patients regain consciousness half an hour after surgery, can drink water within 4 hours, and may be discharged within 6 hours. Postoperative complications and infections are greatly reduced. This is particularly suitable for early-stage patients, and advanced age is not an absolute contraindication.

Can I Be Discharged on the Same Day After Surgery?

Traditional thoracotomy has significant limitations, usually requiring a large 25-30 cm incision with severe trauma. Recovery is slow, possibly taking 6 months, with high risks including pain, pulmonary infection, and heart failure. Minimally invasive surgery requires only a 3 cm incision, 95% avoid transfusion, operation is under 2 hours, and hospital stay is reduced to one week.

Can All Early-Stage Patients Undergo Thoracoscopic Surgery? What Are Its Advantages?

The vast majority of early-stage patients can choose this minimally invasive approach unless they have severe cardiovascular/cerebrovascular disease, cannot tolerate general anesthesia, or have severely impaired lung function. The thoracoscopic incision is smaller, usually only 2-2.5 cm. Patients can usually be discharged 3-4 days after surgery. Traditional thoracotomy requires a 20-30 cm incision with stitches removed after 10-14 days.

What Is the Purpose of Full-Body Evaluation (Enhanced CT, Bone Scan) Before Surgery? If Metastasis Is Found?

Preoperative and postoperative full-body evaluations are important parts of the standard process, including enhanced CT and bone scan, to screen for distant metastasis. If metastasis is found, surgery may not be applicable, as it mainly addresses local issues and is ineffective for distant metastasis.

A 0.7 cm Ground-Glass Nodule Unchanged Since 2016 — Immediate Surgery?

For a stable 0.7 cm ground-glass nodule with no changes since 2016, immediate surgery is not necessary. Nodules smaller than 6 mm and stable are recommended for continuous monitoring. If it grows or changes, surgery may be needed and can usually achieve clinical cure.

For a 1.5×1 cm Ground-Glass Nodule: Wedge Resection or Traditional Lobectomy?

Wedge resection can completely remove the tumor while preserving as much normal lung tissue as possible, crucial for postoperative quality of life and prognosis. Studies show that for peripheral pure ground-glass nodules smaller than 2 cm, local resection has a similar prognosis to traditional lobectomy without increasing recurrence or metastasis risk.

Why Doesn't Lung Resection Affect Lung Function in Early-Stage Cancer?

Under normal physiological conditions, not all five lobes are active. Therefore, removing one lobe usually does not significantly impact daily life. After resection, the remaining lobes compensate by expanding to fill the cavity, maintaining relatively stable overall lung capacity.

Is Pain in the Inferolateral Pectoral Muscle After Surgery Normal?

Pain in the inferolateral pectoral muscle after surgery may be caused by the incision. When the nodule is near the breast under the armpit, the skin above the incision may bulge when standing, causing pain. Such pain may also occur in minimally invasive surgery.

As a Stage 3B Patient Who Had Pneumonectomy, Do I Need Radiotherapy?

Radiotherapy after pneumonectomy requires extra caution. Compared with conservative treatment alone, postoperative consolidation can significantly improve survival. However, due to the advanced nature of Stage 3B, the risk of recurrence and metastasis is as high as 70%.

Can Chinese Patent Medicines Be Used After Surgery?

Use of Chinese patent medicines after surgery can be considered case by case. They have effects of regulating the body and enhancing immunity, which may help alleviate symptoms and reduce recurrence risk.

Is the Recurrence Risk Really Low for Minimally Invasive Adenocarcinoma?

Minimally invasive adenocarcinoma is a subtype with limited local invasion, usually within 5 mm, and low distant metastasis risk. After resection, patients have a high probability of clinical cure, with recurrence and metastasis risk below 1%.

In conclusion, minimally invasive surgery for lung cancer represents a significant advancement: reduced recovery time, lower complication risk, and improved survival rates. For patients facing early-stage lung cancer, this approach offers the best chance for a positive outcome.